

Product datasheet

anti-AAV2 (intact particle) mouse recombinant, A20R, lyophilized, purified, sample

Short overview

Cat. No.	610298S
Quantity	10 µg
Concentration	50 µg/ml after reconstitution with 200 µl PBS

Product description

Host	Mouse
Antibody Type	Recombinant
Isotype	IgG1
Clone	A20R
Immunogen	AAV2 capsids
Formulation	Lyophilized; reconstitute in 200 µl sterile PBS
Binding affinity	KD value (AAV2) = <1.0E-12 M KD value (AAV3) = <1.0E-12 M
Synonym	Adeno-associated virus 2; AAV-2
Conjugate	Unconjugated
Purification	Affinity chromatography
Storage before reconstitution	2-8°C until indicated expiry date
Storage after reconstitution	Up to 3 months at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/thaw cycles
Intended use	Research use only
Application	Dot blot, ELISA, ICC/IF, IP, Neutralization assay
Reactivity	AAV2, AAV2 7m8, AAV3, Anc80
No reactivity	AAV1, AAV11, AAV12, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVDJ, AAVrh10, AAVrh74

Applications

Dot Blot	1:500 (0.1 µg/ml, non-denaturing conditions)
ELISA	Assay dependent
Immunocytochemistry (ICC)	1:20
Immunoprecipitation (IP)	1:5
Neutralization Assay	Assay dependent

Background

For characterization of different stages of infection and very useful for the analysis of the AAV2 assembly process. A20R specifically reacts with intact AAV2, AAV3 and Anc80 particles, empty and full capsids. Recognizes a conformational epitope of assembled capsids, not present in

PROGEN Biotechnik GmbH | Maaßstraße 30 | D-69123 Heidelberg


Tel.: +49 (0) 6221 8278-0 | Fax: +49 (0) 6221 8278-24 | Email: info@progen.com | Web: www.progen.com

2024 April 27 / Version: 610298S/DS-070923ibg | Page 1


denatured capsid proteins and native but unassembled capsid proteins. The antibody cannot be used for immunoblotting. The antibody is also useful for neutralizing experiments. The A20R antibody recognizes the same epitope as the A20 antibody (Cat. No. 61055).

Limited Use Label License: Research Use Only Product is exclusively owned by PROGEN Biotechnik GmbH. The use of these products for the development, manufacturing and sale of secondary products/derivatives which are based on the purchased products and/or which include the purchased product require a royalty based sub-license agreement.


Product images



Dot blot analysis of native AAV2, Anc80 and AAVrh74 capsids (1E+09 capsids) and recombinant AAV2 VP2 protein (500 ng, Cat No. 640824). The nitrocellulose membrane was blocked with 5% dry milk in PBST (PBS + 0.1% Tween 20) for 1 h at RT. The primary antibody anti-AAV2, mouse recombinant, A20R as diluted in blocking buffer (antibody concentration 500 ng/ml) and incubated for 1 h at RT. The secondary antibody goat anti-mouse IgG HRP was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Plus Western Blotting Substrate.



Dot blot analysis of native AAV1-AAV9, AAVrh10, AAVDJ capsids (1E+09-1E+10 capsids) and denatured AAV2 capsids (1E+09-1E+10 capsids, denatured at 95°C for 10 min in sample buffer). The nitrocellulose membrane was blocked with 5% dry milk in PBST (PBS + 0.1% Tween 20) for 1 h at RT. The primary antibody anti-AAV2, mouse recombinant, A20R was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1 h at RT. The secondary antibody goat anti-mouse IgG HRP was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce ECL Plus Western Blotting Substrate.



Neutralization of AAV3-GFP vectors with the A20R antibody. AAV infection was shown in HeLa cells and photos (GFP, CPE, merge) were taken ~48 h post infection. Neutralization was enhanced with increasing A20R concentration.